Literature DB >> 10659996

Phosphatidylinositol 3-kinase contributes to Erk1/Erk2 MAP kinase activation associated with hepatocyte growth factor-induced cell scattering.

S Sipeki1, E Bander, L Buday, G Farkas, E Bácsy, D K Ways, A Faragó.   

Abstract

MAP kinase cascade-dependent responses were investigated during scattering of HepG2 human hepatoma cells stimulated by HGF or phorbol ester. Inhibition of phosphatidylinositol 3-kinase with LY294002 prevented completely the dissociation of cells. Inhibition of MAP kinase kinase (MEK) with PD98059 prevented the development of characteristic morphological changes associated with cell migration. EGF, which failed to induce cell scattering, caused a short-term increase in the phosphorylation of Erk1/Erk2 MAP kinases. On the contrary, HGF or phorbol ester stimulated the phosphorylation of MAP kinases for a long time. Experiments performed with LY294002 indicated that phosphatidylinositol 3-kinase contributed to the HGF-stimulated phosphorylation of Erk1/Erk2. This finding was confirmed by the demonstration that the MAP kinase cascade-dependent expression of a high-Mr (>300 kDa) protein pair appearing in the course of cell scattering was inhibited by LY294002 in HGF-induced cells but was not inhibited in phorbol ester-treated cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10659996     DOI: 10.1016/s0898-6568(99)00060-1

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  22 in total

1.  Transcriptional gene expression profiles of HGF/SF-met signaling pathway in colorectal carcinoma.

Authors:  Xue-Nong Li; Yan-Qing Ding; Guo-Bing Liu
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

2.  PKC controls HGF-dependent c-Met traffic, signalling and cell migration.

Authors:  Stéphanie Kermorgant; Daniel Zicha; Peter J Parker
Journal:  EMBO J       Date:  2004-09-23       Impact factor: 11.598

3.  Endothelial PAS domain-containing protein 1 confers TKI-resistance by mediating EGFR and MET pathways in non-small cell lung cancer cells.

Authors:  Qiang Zhen; Jun-Feng Liu; Jia-Bao Liu; Ren-Feng Wang; Wei-Wei Chu; Ya-Xiao Zhang; Guo-Liang Tan; Xiao-Jian Zhao; Bao-Lei Lv
Journal:  Cancer Biol Ther       Date:  2015-04-01       Impact factor: 4.742

4.  Pregnane X receptor PXR activates the GADD45beta gene, eliciting the p38 MAPK signal and cell migration.

Authors:  Susumu Kodama; Masahiko Negishi
Journal:  J Biol Chem       Date:  2010-12-02       Impact factor: 5.157

5.  A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors.

Authors:  Stephen V Liu; Susan G Groshen; Karen Kelly; Karen L Reckamp; Chandra Belani; Timothy W Synold; Amir Goldkorn; Barbara J Gitlitz; Mihaela C Cristea; I-Yeh Gong; Thomas J Semrad; Yucheng Xu; Tong Xu; Marianna Koczywas; David R Gandara; Edward M Newman
Journal:  Cancer Chemother Pharmacol       Date:  2018-08-20       Impact factor: 3.333

6.  The ERK1/2-hepatocyte nuclear factor 4alpha axis regulates human ABCC6 gene expression in hepatocytes.

Authors:  Hugues de Boussac; Marcin Ratajewski; Iwona Sachrajda; Gabriella Köblös; Attila Tordai; Lukasz Pulaski; László Buday; András Váradi; Tamás Arányi
Journal:  J Biol Chem       Date:  2010-05-12       Impact factor: 5.157

Review 7.  Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.

Authors:  Conor A Bradley; Manuel Salto-Tellez; Pierre Laurent-Puig; Alberto Bardelli; Christian Rolfo; Josep Tabernero; Hajrah A Khawaja; Mark Lawler; Patrick G Johnston; Sandra Van Schaeybroeck
Journal:  Nat Rev Clin Oncol       Date:  2017-04-04       Impact factor: 66.675

8.  Hepatocyte growth factor sensitizes brain tumors to c-MET kinase inhibition.

Authors:  Ying Zhang; Kaitlyn E Farenholtz; Yanzhi Yang; Fadila Guessous; Charles G Dipierro; Valerie S Calvert; Jianghong Deng; David Schiff; Wenjun Xin; Jae K Lee; Benjamin Purow; James Christensen; Emanuel Petricoin; Roger Abounader
Journal:  Clin Cancer Res       Date:  2013-02-05       Impact factor: 12.531

9.  MiR-335 inhibits migration of breast cancer cells through targeting oncoprotein c-Met.

Authors:  Yue Gao; Fan Zeng; Jia-Yan Wu; Hai-Yu Li; Jian-Jun Fan; Li Mai; Ji Zhang; Dong-Mei Ma; Yun Li; Fang-zhou Song
Journal:  Tumour Biol       Date:  2014-12-10

Review 10.  Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy.

Authors:  Vikas Bhardwaj; Tina Cascone; Maria Angelica Cortez; Arya Amini; Jaden Evans; Ritsuko U Komaki; John V Heymach; James W Welsh
Journal:  Cancer       Date:  2013-02-19       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.